Face masks effectively limit the probability of SARS-CoV-2 transmission

Diverse Functional Autoantibodies in Patients with COVID-19

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

The emergence of SARS-CoV-2 variants threatens progress toward control of the Covid-19 pandemic. In a phase 1–2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell response

Event Related Potentials might be an accurate neurophysiological biomarker for early diagnosis of AD and prediction of MCI to AD conversion.

For May 2021, we have selected: Walgaard et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20=:275-283. doi: 10.1016/S1474-4422(20)30494-4.

For June 2021, we have selected the following paper: Dagan N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384:1412-1423. doi: 10.1056/NEJMoa2101765.

Anja Sander, Executive Director of EAN, recommends these sessions at Virtual 2021

The Scientific Panel on Movement Disorders Management Group invites you to join us for the excellent Movement Disorders program at the EAN Virtual Congress. The program has been prepared in collaboration between the EAN and the International Parkinson and Movement Disorder Society – European Section (MDS-ES).

The Lundbeck Foundation is now accepting nominations for next year’s winners of The Brain Prize, the world’s largest prize for neuroscience. Find out about the nomination and selection process, and nominate here: https://lundbeckfonden.com/en/node/4051 The Brain Prize recognizes ground-breaking advances in… Continue Reading